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A B S T R A C T
Higher serum 25–hydroxyvitamin D [25(OH)D] concentrations have been associated with lower risk of
type 2 diabetes. This study compared incidence rates of type 2 diabetes among participants aged 20
years in two U.S. cohorts with markedly different median 25(OH)D concentrations. The median 25(OH)D
concentration in the GrassrootsHealth (GRH) cohort was 41 ng/ml (N = 4933) while in the 2005–6
National Health and Nutrition Examination Survey (NHANES) it was 22 ng/ml (N = 4078) (P < 0.0001). The
adjusted annual incidence rate of type 2 diabetes was 3.7 per 1000 population (95% conﬁdence
interval = 1.9, 6.6) in the GRH cohort, compared to 9.3 per 1000 population (95% conﬁdence interval = 6.7,
12.6) in NHANES. In the NHANES cohort, the lowest 25(OH)D tertiles (<17, 17–24 ng/ml) had higher odds
of developing diabetes than the highest tertile (OR: 4.9, P = 0.02 and 4.8, P = 0.01 respectively), adjusting
for covariates. Differences in demographics and methods may have limited comparability. Raising serum
25(OH)D may be a useful tool for reducing risk of diabetes in the population.
ã 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
According to the Centers for Disease Control (CDC), diabetes
afﬂicts 29.1 million people in the United States, about 9.3% of the
population [1]. Type 2 diabetes accounts for 90–95% of adult
diabetes cases. The CDC expects the number of cases to double or
triple in the next 40 years. Diabetes is the leading cause of kidney
failure, non-traumatic lower limb amputations, and new cases of
blindness among adults and is the seventh leading cause of death
in the United States. The estimated total yearly cost of diabetes in
the United States is $245 billion [1].
Those with type 2 diabetes have lower serum 25–hydroxyvi-
tamin D [25(OH)D] concentrations than their healthy counterparts
[2–4]. Prospective studies [5–16] and randomized controlled trials
[17–20] have found a vitamin D association with type 2 diabetes
and its metabolic indicators. A recent meta-analysis including both
longitudinal cohort studies and randomized controlled trials
of vitamin D supplementation found that higher baseline 25
(OH)D levels in prospective studies predicted a lower diabetes
risk [21]. There was a 43% reduction in type 2 diabetes incidence
(95% conﬁdence interval [CI] = 24–57%) comparing the highest
(>25 ng/ml) to the lowest (<14 ng/ml) category of 25(OH)D.
We hypothesized that individuals in a cohort with higher
serum 25(OH)D concentrations would have lower incidence of
type 2 diabetes than those in a cohort with lower concentrations.
This report presents the incidence of type 2 diabetes
among United States residents aged 20 years and older in
the GrassrootsHealth (GRH) study, a cohort with a median serum
25(OH)D level of 41 ng/ml, compared with estimates for the
2005–2006 National Health and Nutrition Examination Survey
(NHANES) study, a cohort with a median serum level of 22 ng/ml.
Additionally, the relationship between serum 25(OH)D and
incidence of type 2 diabetes was examined. Serum 25(OH)D
concentration was the variable of interest because it is a better
indicator of vitamin D status than supplement intake or sun
exposure because it accounts for multiple input sources and
inter-individual variability in dose response.
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2. Materials and methods
2.1. GrassrootsHealth Cohort
This cross-sectional study utilized baseline data from GRH, a
non-proﬁt public health research organization running a large
prospective population based study allowing participants to
reach and sustain a serum 25(OH)D level of their choice, and
tracking self-reported health status measures. Participants were
individuals who responded to an invitation to attendees at a GRH
seminar in 2008 and others recruited via internet invitations.
There were no exclusion criteria for enrollment; participants
included both genders, and wide ranges of ages and health
statuses. Participation included submission of a home blood spot
25(OH)D test kit and completion of an online health question-
naire. Included in the test results were the normal reference
ranges, information about potential toxicity levels, and suggested
serum 25(OH)D concentrations (40–60 ng/ml) as recommended
by a consortium of scientists and physicians [22]. All participants
have given informed consent and this research study was
approved by the Western Institutional Review Board (Olympia,
WA) WIRB study 1126093.
Between January 2009 and July 2013, participants reported
their gender, age, race, physical activity, and smoking status at
study enrollment. Body mass index (BMI) was calculated using
self-reported weight and height and categorized into 3 groups:
<25, 25–30, >30. Regular exercise was deﬁned as at least
moderate physical activity for at least 20 min, 3 or more days/
week. Race was categorized as “white” versus “non-white” and
smoking status was categorized as “current smoker” versus
“never/former smoker.”
Serum 25(OH)D concentrations were determined by blood spot
test kits analyzed at study enrollment using liquid chromatogra-
phy-mass spectroscopy (LC-MS/MS) by ZRT Laboratory (Beaverton,
OR). ZRT's assay has been validated against the LC-MS/MS
consensus group reporting to the Vitamin D Quality Assessment
Scheme (DEQAS), whose objective is to ensure the analytical
reliability of 25(OH)D assays, with an R2 value of 0.998. LC-MS/MS
has been validated against the DiaSorin Radioimmunoassay (RIA)
method with an R2 value of 0.91 and with a slope not different from
1.0 [23].
In the GRH cohort, an incident case was deﬁned as a self-
reported diagnosis by a doctor of type 2 diabetes within the 12
months prior to enrollment based on the date of diagnosis. A date
of diagnosis before this 12-month period was considered a
prevalent case and excluded. This study included all GRH
participants residing in the United States aged 20 years and
older with no prior history of diabetes before the 12-month
observation period (N = 4933). This age and residency group was
chosen to match the NHANES cohort, which was a sample of the
United States population and collected all covariate data for those
aged 20 years. Age, gender, and race were available for all
participants in this GRH cohort. BMI, smoking status, and physical
activity were available for 90%, 89% and 89% of the cohort
respectively.
2.2. NHANES Cohort
The 2005–2006 NHANES study population was a representa-
tive sample of the civilian, non-institutionalized United States
population. NHANES used a complex, stratiﬁed, multistage,
probability-cluster sampling design that oversampled low
income persons, adolescents, the elderly, Blacks, and Mexican
Americans to produce reliable estimates for these groups.
Detailed survey and examination methods can be found
elsewhere [24]. Brieﬂy, between January 2005 and December
2006, participants reported their gender, age, race, and physical
activity via household interviews. BMI, regular exercise, race, and
smoking status were deﬁned, calculated, and categorized in the
same manner as the GRH cohort mentioned above. Blood samples
were collected by venipuncture in mobile examination centers and
serum 25(OH)D concentrations were determined by using the
DiaSorin RIA kit assay (Stillwater, MN) at the National Center for
Environmental Health, CDC, Atlanta, GA.
In the NHANES cohort, an incident case was deﬁned as a self-
reported diagnosis of diabetes within the 12 months prior to the
health interview. Speciﬁcally, the participant answered ‘yes’ to
the question “Other than during pregnancy, have you ever been
told by a doctor or health professional that you have diabetes or
sugar diabetes?” and answered “12 months ago or less” to “When
was your diabetes diagnosed?”. Participants who answered “more
than 12 months ago” were considered prevalent cases and
excluded. To differentiate between type 2 and type 1 diabetes,
participants who answered ‘no’ to both “Are you taking insulin
now?” and “Are you now taking diabetic pills to lower your blood
sugar?” were considered type 2 diabetes cases. Those who
responded ‘yes’ to “Are you now taking diabetic pills to lower your
blood sugar” (with or without insulin intake) were also
considered type 2 diabetes cases.
This study included all 2005–2006 NHANES participants
aged 20 years and older with no prior history of diabetes before
the 12-month observation period and who completed the
physical exam component where a valid 25(OH)D measurement
was obtained (N = 4078). This age group was chosen because
participants <20 years old were not assessed for smoking status, a
key diabetes risk factor. All participants aged 1 year and older
were eligible for the physical exam but among those 20 years,
484 did not participate in this component. Age, gender, race,
smoking status, and physical activity were available for all
participants in this NHANES cohort. BMI was available for all
diabetes cases and 96% of the cohort.
2.3. Statistical Methods
Chi-square tests were used to test for differences between the
GRH and NHANES cohorts. The unadjusted incidence rate of type
2 diabetes was calculated for the GRH and NHANES cohorts. An
indirect rate adjustment was calculated according to the diabetes
risk factors that were signiﬁcantly different between the cohorts
(age, gender, race, smoking status, and BMI). The NHANES
population was used as the standard to simultaneously adjust
for these risk factor differences in the GRH population.
Speciﬁcally, gender, age, race, smoking status, and BMI-speciﬁc
incidence rates from the NHANES population were applied to the
gender, age, race, smoking status, and BMI distribution of the GRH
cohort to estimate the expected number of cases. Participants
with missing covariate data were distributed on the basis of
existing data for each cohort. The ratio of observed to expected
number of cases (standardized incidence ratio) and its 95%
conﬁdence interval (CI) were calculated. The Mantel-Haenszel
(M-H) odds ratio estimate was calculated for the lowest 25(OH)D
tertile (<17 ng/ml) versus the highest tertile (25 ng/ml) for the
NHANES cohort, adjusting for age. Logistic regression was used to
determine the association between 25(OH)D serum levels and the
risk of developing type 2 diabetes within the NHANES cohort,
adjusting for age, gender, race, BMI, physical activity, and smoking
status. Modeling was conﬁned to participants with valid values
for all of the involved variables. The relationship between 25(OH)
D serum levels and type 2 diabetes risk could not be assessed
within the GRH cohort due to insufﬁcient number of cases.
Statistical analyses were performed using SPSS statistics version
22 (IBM, Armonk, NY).
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3. Results
The median serum 25(OH)D concentration in the GRH cohort
was 41 ng/ml (I-Q range: 31–55) and in the NHANES cohort was
22 ng/ml (I-Q range: 15–28) (P < 0.0001). In the GRH cohort, 77% of
participants reported taking vitamin D supplements with a median
daily intake of 2400 IU. In the NHANES cohort, 30% reported taking
vitamin D supplements with a median daily intake of 400 IU.
Among the 10 individuals who developed diabetes in the GRH
cohort, 5 were below the median cohort serum level of 41 ng/ml
and 5 were equal to or above it (Fig. 1). Among the 38 individuals
who developed diabetes in the NHANES cohort, 31 were below the
median cohort serum level of 22 ng/ml and 7 were equal to or
above it. The GRH cohort had a statistically signiﬁcant higher
proportion of participants that were older, female, white, never/
former smokers, and had a lower BMI (Table 1). Physical activity
did not differ between the cohorts.
The unadjusted annual incidence rate within the GRH population
was 2.0 per 1000 population (95% CI = 1.0, 3.6), compared to 9.3 per
1000 population (95% CI = 6.7, 12.6) within the NHANES population.
After indirect adjustment for age, gender, race, smoking status, and
BMI, the expected number of cases was 25 compared to the 10
observed GRH cases. The standardized incidence ratio was 0.40 (95%
CI = 0.20, 0.71), or 60% lower risk in the GRH cohort (Fig. 2). The
adjusted annual incidence rate within the GRH cohort was 3.7 per
1000 population (95% CI = 1.9, 6.6).
Using the Mantel-Haenszel (M-H) method to adjust for age, the
lowest 25(OH)D tertile (<17 ng/ml) had higher odds of developing
diabetes than the highest tertile (25 ng/ml) in the NHANES
population (odds ratio: 8.0, P = 0.001). In the NHANES cohort, the
lowest 25(OH)D tertiles (<17, 17–24 ng/ml) had higher odds of
developing diabetes than the highest tertile (odds ratios: 4.9,
P = 0.02 and 4.8, P = 0.01 respectively), adjusting for age, gender,
race, BMI, physical activity, and smoking status (Table 2).
4. Discussion
The adjusted incidence rate of type 2 diabetes in a cohort with
markedly higher than usual median serum 25(OH)D values (GRH)
was less than half that in a cohort with lower median 25(OH)D
(NHANES). While the cross-sectional method of calculating
incidence for the GRH prospective cohort was not traditional, this
method was chosen to parallel the procedure used in the NHANES
study. To assess how this may have inﬂuenced the results, the
incidence rate for those diagnosed with type 2 diabetes after
enrollment among the at-risk population was calculated and found
to be 1.2 per 1000 person-years (95% CI = 0.37, 2.81). This rate was
comparable to the cross-sectional GRH rate and signiﬁcantly lower
than the NHANES rate.
Within the NHANES cohort, those with serum 25(OH)D levels
below 25 ng/ml had almost 5 times the odds of developing diabetes
compared to those with serum 25(OH)D levels 25 ng/ml. Other
studies have found a similar reduction in risk of type 2 diabetes. A
nested case-cohort study found a 50% lower hazard of developing
type 2 diabetes for those with serum 25(OH)D levels <20 ng/ml
compared to those with levels 32 ng/ml (95% CI = 0.32, 0.76) [14].
Anotherstudyfounda42%reductionintheriskofprogressiontotype
2 diabetes from prediabetes or normal glucose tolerance in the
highest 25(OH)D quartile (>28 ng/ml) compared to the lowest
quartile (<18 ng/ml) [11]. Amongthosewith prediabetes, therewasa
62% reduction in the risk of diabetes comparing the highest quartile
to the lowest quartile. A study presented at the 2014 Endocrine
Society Meeting found a 58% reduction in the progression from
prediabetes to diabetes in a group treated with calcium and 60,000
IU/week of vitamin D for eight weeks and then monthly compared to
a group given only calcium supplements [25].
The distribution of the GRH cases across the 25(OH)D serum
level spectrum, shown in Fig. 1, allows a very interesting
interpretation. A recently published article presented guidelines
to standardize individual studies of nutrients and meta-analyses
based on the biological response to nutrients [26]. The measure-
able beneﬁt for a nutrient-speciﬁc response is found within a
narrow response region, with a ﬂat response above and below this
region (Fig. 3). Taking into account the sigmoidal nature of the
nutrient response, a recent study used successive regression
models to localize the association of vitamin D status with insulin
resistance to the range of 16–36 ng/ml; with a ﬂat extension for
levels >32–36 ng/ml [27]. In the GRH cohort, 71% of participants
had serum levels above 32 ng/ml and outside the range of
association found in that study. With this in mind, the results of
both cohorts would be consistent with a sigmoidal response
between 25(OH)D and diabetes risk where there is a ﬂat response
below 10 ng/ml, a clinical response between about 10 ng/ml
and 30–35 ng/ml, and a plateau of no additional effect above
30–35 ng/ml.
A recent systematic review and meta-analysis of randomized
controlled trials found no effect of vitamin D supplementation on
diabetes prevention [28]. All four studies included in the meta-
analysis regarding progression to diabetes reported null results
[29–32]. One of these studies had a relatively small number of
Fig. 1. Frequency distribution of serum 25–hydroxyvitamin D [25(OH)D] for GrassrootsHealth (GRH) (N = 4933) and NHANES (N = 4078) cohorts.
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participants and three studies administered vitamin D doses 800
IU/day, an intake amount that is unlikely to raise basal levels to a
sufﬁcient status, and did not limit their study population to only
vitamin D deﬁcient individuals. The nutrient-speciﬁc response
depends on an individual's basal status where an increase in intake
will produce a beneﬁt in a deﬁcient individual but will have a null
effect in a replete individual [26]. Also, treating the relationship as
linear, spread across the entire 25(OH)D range instead of a
sigmoidal response would dilute the effect and may explain why
some studies did not ﬁnd a vitamin D association with diabetes.
Additional randomized controlled trials that base their design on
nutrient physiology are needed to accurately assess the association
between vitamin D and diabetes.
Limitations of this study include the use of self-report data
where recall bias may have occurred, and differences in methods
and demographics between the GRH and NHANES cohorts may
have limited comparability. The GRH cohort of individuals was
self-selected for health consciousness and NHANES is a popula-
tion-based sample. Also, two different assays were used to
determine serum 25(OH)D concentration and while these
methods were both calibrated against LC-MS/MS with high
correlation, systematic differences are possible. This analysis took
into account cohort differences for many of the key risk factors for
type 2 diabetes but there were some factors such as waist
circumference, diet, and socio-economic indicators that were not
available. Lack of adjustment for these covariates or other
unavailable or unknown variables may have inﬂuenced the
outcome. Since multivariate logistic regression was conducted
only within the NHANES cohort, analysis of the association
between serum 25(OH)D and risk of type 2 diabetes was not
affected by this limitation. Also, this study assumed the 25(OH)D
levels measured in participants at enrollment were similar to
their levels in the 12 months prior, back to the beginning of the
period used to measure diabetes incidence.
Table 1
Demographic characteristics of GrassrootsHealth (GRH) (N = 4933) and NHANES (N = 4078) cohorts.
Characteristic GRH
N (%)
NHANES
N (%)
x2 P
Age (years) 600.13 <0.0001
20–39 892 (18%) 1671 (41%)
40–59 2382 (48%) 1260 (31%)
60 1659 (34%) 1147 (28%)
Gender 206.31 <0.0001
Male 1632 (33%) 1956 (48%)
Female 3301 (67%) 2122 (52%)
Race 1991.86 <0.0001
White 4584 (93%) 2107 (52%)
Non–white 347 (7%) 1971 (48%)
BMI (kg/m2) 367.22 <0.0001
<25 2463 (55%) 1416 (36%)
25–30 1332 (30%) 1395 (36%)
>30 654 (15%) 1105 (28%)
Physical activity 1.46 0.227
Regular exercise 3046 (69%) 2864 (70%)
Non-regular exercise 1367 (31%) 1214 (30%)
Smoking status
Current smoker 161 (4%) 904 (22%) 656.83 <0.0001
Never/former smoker 4219 (96%) 3171 (78%)
Fig. 2. Type 2 diabetes incidence rates in GrassrootsHealth (GRH) (N = 4933) and NHANES (N = 4078) cohorts.
242 S.L. McDonnell et al. / Journal of Steroid Biochemistry & Molecular Biology 155 (2016) 239–244
While there are limitations to this study, these results add to the
growing body of evidence supporting the association between
higher serum 25(OH)D levels and a reduced risk of type 2 diabetes
[5–21,25,27]. Higher vitamin D status has also been associated in
other observational studies with a reduced risk of type 1 diabetes,
cancer, myocardial infarction, and multiple sclerosis [22,33–38].
The Institute of Medicine (IOM) recommends levels of 20 ng/ml
and considers 4000 IU/day as the safe upper intake level (SUIL)
[39]. Other investigators and physicians have proposed a 25(OH)D
concentration between 40 and 60 ng/ml as a safe range to achieve a
reduction in risk of diseases associated with vitamin D deﬁciency
[40–43]; this range can generally be achieved with the IOM SUIL of
4000 IU/day [44–45].
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